BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioVisioN AG Receives United States Patent For Peptide-Biomarker Discovery And Identification Technology


10/19/2005 5:13:14 PM

HANOVER, Germany--(BUSINESS WIRE)--April 7, 2005--The patent office of the United States of America has granted the patent for BioVisioN's core technology, the "Differential Peptide Display(R)" (DPD), for the discovery and identification of peptide biomarkers. The methods of this German biotech company allow the analysis and comparison of peptides in any biological sample and represent the most important component of the company's Peptidomics(R) technologies. Peptides are being valued and intensely researched by the pharmaceutical industry because of their potential as biomarkers and drugs. BioVisioN has already received patents for the DPD-Technology in Europe and other important pharmaceutical markets. Using mass spectrometry BioVisioN's Differential Peptide Display analyses virtual every peptide in clinical samples like blood or urine, offering sensitivities down to picograms per milliliter. Using bioinformatic software tools developed in-house, the quantitative comparison of hundreds of samples is possible, making the technology suitable for biomarker discovery within clinical trials. The comparison of samples from e.g. patients and healthy controls shows up quantitative differences in peptide content characteristic of the disease studied. This provides for the identification of new diagnostic markers or biomarkers and also therapeutic leads and targets.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES